Lunge und Autoimmunerkrankungen - Therapie

Zusammenfassung

Die Therapie pulmonaler Manifestationen bei Autoimmunerkrankungen hängt neben der Art und Schwere der Lungenmanifestation von der zu Grunde liegenden Erkrankung ab. Im vorliegenden Übersichtsartikel werden die Therapieprinzipien bei Vaskulitiden, rheumatischen Erkrankungen und Kollagenosen beschrieben.

Summary

Pulmonary manifestations of autoimmune diseases are treated depending on the involved lung structure and the underlying disorder. In this review the therapeutic approach in the case of vascultitis, rheumatoid arthritis and connective tissue disease will be presented.

Schlüsselwörter

Alveolitis - Diffuse alveoläre Hämorrhagie - Fibrose - Kollagenose - Pulmonale Hypertonie - Vaskulitis

Key words

alveolitis - connective tissue disease - diffuse alveolar haemorrhage - fibrosis - pulmonary hypertension - vasculitis

Literatur

• 1 Cherin P, Brenot F, Bletry O. et al . Pulmonary hypertension in SLE: Hemodynamic effects of vasodilating agents.  Lupus. 1995;  4 171S-176S
• 2 De Groot K, Rasmussen N, Bacon P A. et al . Randomized trial of cylcophosphamid versus methotrexat for induction of remission in early systemic antineutrophil cytoplasmatic antibody-associated vasculitis.  Arthritis Rheum. 2005;  52 2461-2469
• 3 De Remee R A. WegenerŽs granulomatosis.  Ann Intern Med. 1992;  117 619-620
• 4 Fauci A S, Haynes B F, Katz P, Wolff S M. WegenerŽs granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.  Ann Intern Med. 1983;  98 76-85
• 5 Hoyles R K, Ellis R W, Wellsbury J. et al . A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cylcophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.  Arthritis Rheum. 2006;  54 3962-3970
• 6 Hunninghake G W, Fauci A S. Pulmonary involvement in the collagen vascular disease.  Am Rev Respir Dis. 1979;  119 471-503
• 7 Jayne D. Evidence-based treatment of systemic vasculitis.  Rheumatology (Oxford). 2000;  39 585-595
• 8 Jayne D, Rasmussen N, Andrassy K. et al . A randomized trail of maintance therapy for vasculitis associated with antineutrophil antibody-associated vasculitis.  N Engl J Med. 2003;  349 36-44
• 9 Klemmer P J, Chalermskulrat W, Reif M S. et al . Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis.  Am J Kidney Dis. 2003;  42 1149-1153
• 10 Matthay R A, Schwartz M I, Petty T L. et al . Pulmonary manifestations of systemic lupus erythematosus. Review of twelve cases of acute lupus pneumonitis.  Medicine. 1975;  54 397-409
• 11 Rihova Z, Jancova E, Merta M. et al . Daily oral versus pulse intravenous Cyclophosphamide in the therapy of ANCA-associated vasculitis: preliminary single center experience.  Prague Med Rep. 2004;  105 64-68
• 12 Rubin L J, Badesch D B, Barst R J. et al . Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
• 13 Schwarz M I, Matthay R A, Sahn S A. et al . Interstitial lung disease in polymyositis und dermatomyositis: Analysis of six cases and review of the literature.  Medicine. 1979;  55 89-104
• 14 Sullivan W D, Hurst D J, Harmon C E. et al . A prospective evaluation emphazising pulmonary involvement in patients with mixed connective tissue disease.  Medicine. 1984;  63 92-107
• 15 Tashkin D P, Elashoff R, Clements P J. et al . Cylcophosphamide versus placebo in scleroderma lung disease.  N Engl J Med. 2006;  354 2655-2666